Vireo Growth (VREOF): The Cannabis Roll-Up Taxed While Losing Money
🎙 Listen — Q&A podcast
RoboSystems Cannabis Coverage · FY2025 10-K (filed March 17, 2026) + Q1 FY2026 10-Q (filed May 12, 2026) · all figures verified live against the RoboSystems SEC graph (CIK 0001771706) unless attributed otherwise · management commentary from the Q1 2026 earnings call and investor presentation · priced late June 2026
The Hook
Vireo Growth lost about forty million dollars before taxes in 2025. Then it got a twenty-eight million dollar tax bill. That is not a typo, and it is not a rounding error — it is the single most honest picture of what Section 280E does to an American cannabis company. A normal business that loses money pays no income tax; it banks a loss. Vireo, because the IRS still treats the plant it sells as a Schedule I narcotic, paid roughly forty-two million dollars of cash income taxes in a year it never earned a pretax profit. Its effective tax rate for 2025 was negative seventy-one percent.
And here is the part nobody is modeling: this is the fastest-growing operator in the entire coverage set. Revenue jumped 170 percent in 2025 and another 333 percent year-over-year in the first quarter of 2026, as a frantic six-month buying spree turned a sub-hundred-million-dollar regional player into a roughly four-hundred-million-dollar-run-rate multi-state operator — soon to be six hundred million once the pending Fluent deal closes. The market caps it around half a billion dollars. Sitting on the balance sheet, mostly unnoticed, is a one-hundred-twenty-million-dollar pile of disputed back taxes that quadrupled in a single year. This is a roll-up racing to outrun a tax code written for drug dealers — and the whole thesis turns on whether that code changes before the bill comes due.
Company Snapshot
Vireo Growth Inc. (OTCQX: VREOF; CSE: VREO; CIK 0001771706) is a vertically integrated, Minneapolis-headquartered multi-state cannabis operator — cultivation, manufacturing, wholesale and retail under banners including Green Goods and Green Dragon. After years as a small, medical-focused operator, Vireo spent 2025–2026 reinventing itself as the sector's most aggressive consolidator, merging in Deep Roots (Nevada), Proper (Missouri) and Wholesome (Utah), then closing Schwazze, the PharmaCann Colorado MSA, the Eaze delivery platform and Hawthorne — and, subsequent to quarter-end, agreeing on April 30, 2026 to an all-stock acquisition of Florida's Fluent Corp and a New York joint venture with Glass House Brands. On a pro-forma basis, management says the combined company is now the fourth-largest US cannabis company by revenue. Its operating footprint spans roughly nine states — Nevada, Missouri, Minnesota, Utah, Maryland, Colorado/New Mexico, New York, California and Florida. On June 5, 2026 it executed a 30-for-1 share consolidation — roughly 1.46 billion subordinate voting shares collapsed to about 48.5 million — as preparation for a potential US exchange uplisting. This coverage is built on the FY2025 10-K, the Q1 FY2026 10-Q, and management's Q1 2026 call and deck.
The Financial Story
Start with the growth, because it is real and it is violent. Revenue went from $74.6M in 2022 to $88.1M in 2023 to $99.4M in 2024 — a respectable regional grower — and then to $268.8M in 2025, up 170 percent. The first quarter of 2026 alone did $106.2M, up from $24.5M a year earlier. That is not organic growth; it is acquisition accounting, and the balance sheet shows it: total assets tripled from $279M to $817M in twelve months (and to $929M by March), goodwill went from literally zero to $124M, and shareholders' equity climbed from $56M to $307M — funded almost entirely by issuing stock to sellers. The "so what" is that the Vireo you can analyze today barely existed eighteen months ago, and the trailing numbers understate a business now running north of a $400M annual rate.
Underneath the deals, the operating engine is actually turning over. Gross margin expanded to 55.8 percent in Q1 2026, the company posted positive operating income of $9.0M against a $1.0M operating loss for full-year 2025, and adjusted EBITDA hit $32.7M — a 30.8 percent margin, up 391 percent year-over-year and up 11 percent sequentially from Q4's $29.5M (company figures). Operating cash flow turned positive too: +$3.7M for 2025 (versus negative $10.2M in 2024) and +$11.9M in Q1 2026 — against $137.8M of cash on hand. The revenue is also more diversified than the "Minnesota company" label suggests: in Q1, Nevada was actually the largest state at $27.6M, ahead of Missouri ($25.4M) and Minnesota retail ($18.2M), with Utah, Maryland, Colorado and a wholesale-led New York filling out the mix. The integration is showing scale.
But hold the adjusted-EBITDA number up to the light, because it tells the whole story. That $32.7M is built by adding back $16.1M of income taxes and roughly $15.7M of M&A transaction costs to a GAAP EBITDA of $10.3M. In other words, the gap between a business that looks healthy on adjusted EBITDA and one that reported a $20.3M net loss is, almost exactly, 280E plus the cost of the buying spree. Adjusted EBITDA flatters; the tax bill is cash.
Then 280E undoes all of it. In 2025 Vireo carried $127.1M of gross profit down to a breakeven operating line and a $39.9M pretax loss — most of that gap is heavy interest, including $14.3M of finance-lease interest from sale-leaseback cultivation assets, plus acquisition transaction costs. A normal company stops there: pretax loss, no tax. Vireo instead booked $28.2M of income tax expense — $41.6M of current tax, partly offset by a $13.4M deferred benefit — producing the $68.1M net loss and that negative 70.7 percent effective rate. The tax footnote names the culprit directly: "uncertain tax positions" subtracted 59 percentage points from the rate ($23.6M) and penalties and interest on those positions another 18 points ($7.2M). That is 280E, dressed in accounting language.
The most underappreciated number in the whole filing is on the balance sheet. Vireo's unrecognized tax benefit reserve jumped from $33.3M to $120.0M in a single year — roughly $134M including penalties and interest by the first quarter. That reserve is, in plain terms, the accrued 280E back taxes Vireo has not paid because it is taking the position it shouldn't owe them: the company has gone so far as to file amended returns for 2020 through 2022 claiming cannabis activity isn't subject to 280E at all — an aggressive refund position the IRS is actively clawing back across the industry. And here is the roll-up twist: more than $50M of that one-year jump came not from Vireo's own operations but from 280E liabilities it inherited by acquiring other companies (it recognized $14.9M and $24.9M of pre-acquisition uncertain-tax positions on two single days in June 2025 alone). So the buying spree isn't only acquiring revenue — it's acquiring other operators' unpaid tax problems. The reserve equals roughly a quarter of Vireo's entire market value, and the 2026 rescheduling relief, which is prospective only, does nothing to erase it.
One distinction from its peers is worth flagging: Vireo's $124M of goodwill and $117M of intangibles are brand new, created by deals struck in 2025 and 2026. Unlike Verano (a $258M loss and impairment-heavy 2025) or the sector's wave of boom-era write-downs, Vireo carries essentially no legacy impairment risk — but it carries the opposite risk, that some of these freshly minted deals were struck at prices a slower market won't validate. The goodwill hasn't been tested yet.
Catalyst Scenarios — How the Math Changes
280E relief — the prize is the cash, not the headline. The cleanest way to see what's at stake: Vireo's current income tax expense was $18.3M in Q1 2026 alone — annualize that and the company is handing the IRS on the order of $70M of cash a year, equal to roughly 14 percent of its entire market capitalization, in a period when it is barely profitable pretax. If a broad Schedule III order removes 280E, the overwhelming majority of that cash drain disappears, and a company posting positive operating income flips from structural net loss to genuine profitability. On the 2025 numbers, stripping the $28.2M of tax turns a $68.1M net loss into roughly a $40M loss — still negative, because of interest, but $28M better; on the forward run-rate, where operating income is positive, the same relief is the difference between losing money and making it.
Medical versus adult-use — Vireo is better positioned than the average MSO. The April 2026 relief is medical-only, and Vireo's mix tilts that way more than most. Its pending Fluent acquisition is essentially a Florida medical business (Florida has no adult-use market until at least 2028), which means a large slice of pro-forma revenue qualifies for relief now. Minnesota — Vireo's home market — ran medical-only until adult-use launched in September 2025. The catch is the ~$134M back-tax reserve: the prospective fix doesn't settle it, and for a still-thinly-capitalized roll-up an un-negotiable historical 280E balance is a real going-concern question, not a footnote.
Consolidation — Vireo is the buyer, which cuts both ways. While AYR's equity was wiped out and Cannabist went to Chapter 15, Vireo went shopping, using its stock as currency to roll up distressed and sub-scale assets at cycle-bottom prices. CEO John Mazarakis frames the discipline tightly: he says he "despise[s] CapEx, especially when there's meaningful regulatory uncertainty," and wants projects that return their capital "cash-on-cash in one year" — which is why Vireo had Fluent sell its Texas license rather than fund a build-out into an uncertain licensing regime. He calls Florida "almost like an orphan asset," the company's "first meaningful integration," with little overlap (~5 stores) between Fluent and Vireo's existing Green Dragon footprint, which he says is already growing "60 to 80 percent" in the state — and he likes that Vireo went in "unlevered." That is the optimistic read: scarce capital is a moat, Vireo is on the right side of it, and management is buying cheap and integrating fast. The pessimistic read is that an all-stock roll-up at a ~$0.40 share price is diluting relentlessly, the 70-plus-store Florida integration is unproven, and the Fluent deal — announced April 30, expected to close Q4 2026, with ~38 percent of Fluent holders committed — still has to clear court, shareholder and regulatory approvals plus a debt equitization before any of the pro-forma math is real.
Minnesota moat + uplisting optionality. Vireo's Green Goods is one of only a handful of operators that could sell adult-use cannabis on day one of Minnesota's September 2025 launch — and the state is in a structural supply shortage, with wholesale flower above $4,000 a pound and a market that has already done roughly $60M year-to-date and is projected near $430M for 2026. Management's plan, in Mazarakis's words, is to "be the market leader by virtue of being the largest producer in the state" — by a "factor of two" once new cultivation comes online imminently — at an EBITDA margin he pegs "north of 60 percent." An incumbent grower in a price-protected, undersupplied home market is exactly the kind of asset that benefits while newcomers scramble for product. The 30-for-1 consolidation, meanwhile, is the visible first step toward the Trulieve-style uplisting playbook — though, like Curaleaf and Verano, Vireo has only done the prep, not the listing, and has no confirmed exchange ticker.
Valuation — What It's Worth If It's a Normal Business
The honest starting point is that Vireo is genuinely hard to value mid-transformation, which is why the disagreement is so wide. On a standalone basis the market caps it around $445–510M with an enterprise value near $785M; on a pro-forma basis including Fluent, the comps set (SSC, priced late May) puts market cap near $687M and EV near $982M. Now anchor that to the company's own run-rate, not just analyst estimates: Q1 adjusted EBITDA of $32.7M annualizes to roughly $131M, and management's pro-forma adjusted EBITDA of $42.2M for the quarter annualizes to roughly $169M. That puts the standalone enterprise value at about 6 times run-rate adjusted EBITDA, and the pro-forma EV near 5.8 times — squarely in line with the comps' forward EV/EBITDA of ~5.5x for 2026 and ~4.1x for 2027, and right around the Tier 1 MSO average of ~4.7x rather than at a premium. The trailing multiples that look expensive (~13–17x) are simply the optical artifact of acquisitions that weren't owned for the full year.
Two lenses bracket the range, both framed as implied value under stated assumptions, not a price target. A scenario DCF would carry an elevated discount rate appropriate to a Schedule I, OTC-listed, serially diluting roll-up; in a base case where 280E persists, free cash flow stays suppressed by ~$70M of annual cash taxes and the value sits roughly where the market has it — the price is, in effect, pricing in that the tax code does not change. In a rescheduling case where 280E is removed, that $70M annual drain converts toward free cash flow, and a forward EBITDA base in the low-200-million range (implied by the comps) re-rates. The cross-sector lens makes the upside concrete: consumer-staples and health-and-wellness peers trade at roughly 10–14x EV/EBITDA; even an 8x multiple on a 280E-normalized forward EBITDA implies an enterprise value materially above the current ~$785–982M. The band across base / partial-catalyst / full-catalyst is therefore wide and skewed upward — but every dollar of that upside is contingent on a federal action that has not yet happened and a roll-up that still has to integrate.
Risks and Open Questions
The risks here are specific and they are large. The ~$134M back-tax reserve is the headline risk — if the IRS prevails on retroactive 280E (as it is fighting to, with clawbacks already landing on peers, and against Vireo's own amended-return refund claims), a thinly capitalized roll-up that has been absorbing other operators' unpaid tax positions could face a liability it cannot pay. The catalyst itself is unresolved: the broad rescheduling hearing only began June 29, 2026 and runs into July, the medical-only order faces a D.C. Circuit challenge, and adult-use relief is not guaranteed. The capital structure is a moving target — about $219M of term/convertible debt plus ~$180M of leases, and although Vireo refinanced into a cheaper first-lien term loan (roughly SOFR plus 4 percent, down from a punishing prime-plus-10.375-percent-plus-PIK facility), the maturity schedule has a real wall: only ~$28M comes due across 2026–2027, but $117M matures in 2028 and needs refinancing in a still-scarce-capital market — on top of an all-stock acquisition machine that dilutes shareholders with every deal. The Fluent deal could slip or break, in which case the pro-forma revenue and EV everyone is quoting evaporates. And the goodwill is untested — these are fresh deals, and a slower market could force the write-downs Vireo has so far avoided. The share-symbol transition (the temporary VREOD ticker, the 30-for-1 consolidation) also means quoted prices across data feeds are currently inconsistent — buyers should verify the basis.
The Bottom Line
Vireo is the highest-beta way to express the cannabis rescheduling thesis in the coverage set: the fastest grower, the purest 280E victim, the most aggressive consolidator, and the most balance-sheet leverage to a federal switch flipping. The nuance worth respecting is that management isn't betting on that switch — CEO Mazarakis explicitly says he tries to "remove the noise of things I cannot control" and is building a company that can "perform if there is meaningful regulatory change, or if there isn't," on the theory that "the best balance sheet and the best team creates the best income statement." That reframes the thesis usefully: underneath the tax story is a real operating business doing ~$33M of quarterly adjusted EBITDA at expanding margins, a genuine Minnesota production moat, and ~$138M of cash — and rescheduling is free optionality on top, not the whole case. Today it's a fast-growing roll-up paying ~$70M a year in taxes it arguably shouldn't owe, carrying a ~$134M historical tax overhang (some of it inherited), with a 2028 debt maturity to clear and relentless dilution. If 280E falls and Fluent closes, the same business is the fourth-largest US operator with positive operating income, a Minnesota moat, and forward multiples already at the sector average — with cross-sector re-rating optionality on top. If the catalyst stalls, the operating story still has to carry the tax bill, the 2028 wall and the dilution. The framework, not a recommendation: watch the June–July DEA hearing, the Fluent close, and the current income-tax line each quarter — that line is where rescheduling will show up first.
This analysis was built with RoboSystems, an open-source platform for direct access to structured SEC filing data. Not investment advice. No price targets. No paid promotions. New customers get 50% off your first month with code CANNABIS50.